文献速递瓣膜外科

二叶式主动脉瓣患者经导管与外科主动脉瓣置换的比较

Transcatheter vs Surgical Aortic Valve Replacement in Bicuspid Aortic Valves.
PubMed 文献 · Ann Thorac Surg · 2024-12-10

该研究基于美国医保住院索赔数据库,纳入2018至2022年因二叶式主动脉瓣接受单纯经导管主动脉瓣置换(TAVR)或外科主动脉瓣置换(SAVR)的11289例患者,经双重稳健风险调整后发现,TAVR与较低的手术死亡率相关,但起搏器植入、长期卒中和全因死亡率均高于SAVR,在年轻低危亚组中结果相似。

要点

  • 在二叶式主动脉瓣患者中,TAVR与较低的手术死亡率相关,但起搏器植入、长期卒中和全因死亡率均高于SAVR。
  • 年轻低危亚组(<75岁且外科风险<4%)中,TAVR的长期卒中和复合终点(卒中、瓣膜再干预或死亡)风险仍高于SAVR。
  • 二叶式主动脉瓣患者选择TAVR时需权衡早期获益与长期卒中及死亡风险。

核心结论

  • 在二叶式主动脉瓣的医保受益人中,TAVR与较低的索引住院死亡率相关,但长期卒中风险和全因死亡率高于SAVR,即使在最年轻低危患者中也是如此。

研究设计与样本

  • 基于美国医疗保险和医疗补助服务中心住院索赔数据库的回顾性队列研究,纳入2018至2022年因二叶式主动脉瓣接受单纯SAVR或TAVR的11289例患者(SAVR 8123例,TAVR 3166例)。
  • 采用经验证的指标评估合并症和衰弱,并通过逆概率加权、多水平回归模型和竞争风险时间事件分析进行双重稳健风险调整。
  • 亚组分析评估了年龄<75岁且外科风险<4%的患者(SAVR 5393例,TAVR 1731例)。

临床怎么用

  • 在为二叶式主动脉瓣患者选择TAVR时,应充分考虑其较高的起搏器植入、长期卒中和全因死亡风险,尤其对于年轻低危患者。
  • 与SAVR相比,TAVR可能带来较低的手术死亡率,但需权衡长期获益与风险。

局限性

  • 研究基于行政索赔数据库,可能存在编码不准确和未测量混杂因素。
  • 研究为回顾性观察性设计,不能确立因果关系。
  • 结论仅适用于美国医保受益人群体,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent approval of transcatheter aortic valve replacement (TAVR) in patients at lower risk profiles has resulted in a real-world expansion in patients with bicuspid aortic valves (BAV), otherwise excluded from trials comparing TAVR with surgical aortic valve replacement (SAVR). This study compared perioperative and longitudinal outcomes between BAV patients undergoing TAVR vs SAVR. METHODS: Using the United States Centers for Medicare and Medicaid Services inpatient claims database, we evaluated all beneficiaries with BAV undergoing isolated SAVR or TAVR (2018-2022). Comorbidities and frailty were accounted for using validated metrics with doubly robust risk adjustment using inverse probability weighting, multilevel regression models, and competing-risk time to event analysis. Subgroup analysis evaluated patients <75 years with low surgical risk (<4%). RESULTS: The study included 11,289 BAV patients (8123 SAVR and 3166 TAVR). Accounting for age, comorbidities, and frailty, TAVR was associated with lower procedural mortality (odds ratio, 0.40; P < .001) but higher pacemaker (12.4% vs 2.3%; odds ratio, 5.4; P < .001), longitudinal stroke (2.4% vs 1.5%; hazard ratio [HR], 1.35; P < .001), and all-cause mortality (8.8% vs 5.7%; HR, 1.49; P < .001) compared with SAVR. The young low-risk subgroup (5393 SAVR and 1731 TAVR) highlighted similar findings, with TAVR associated with higher longitudinal stroke (2.1% vs 1.7%; HR, 1.22; P = .017) and composite stroke, valve reintervention, or death (8.1% vs 5.9%; HR, 1.37; P < .001) compared with SAVR. CONCLUSIONS: Among Medicare beneficiaries with BAV, TAVR was associated with lower index in-hospital mortality but also lower 5-year risk-adjusted freedom from longitudinal stroke compared with SAVR, even in the youngest low-risk patients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Mehaffey JH, Jagadeesan V, Kawsara M, et al. Transcatheter vs Surgical Aortic Valve Replacement in Bicuspid Aortic Valves. Ann Thorac Surg. 2024. PMID: 39662655. doi:10.1016/j.athoracsur.2024.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。